LifeMD, Inc. announced on March 31 2026 that it has launched a new Wegovy® (semaglutide) subscription program in partnership with Novo Nordisk, marking the first and only GLP‑1 subscription offering of its kind in the United States.
The subscription model offers patients structured pricing that can save up to $1,200 annually on injectable Wegovy® and up to $600 on oral therapy, providing a predictable cost structure that encourages adherence and reduces out‑of‑pocket expenses.
Patients enroll through LifeMD’s virtual care platform and receive a comprehensive care package that includes virtual visits, ongoing clinical oversight, nationwide diagnostic testing, and simplified billing and payment, all designed to streamline the patient experience and support long‑term treatment success.
The launch expands LifeMD’s weight‑management portfolio and deepens its integration with Novo Nordisk’s NovoCare® pharmacy program, positioning the company to capture a larger share of the rapidly growing GLP‑1 market while delivering tangible cost savings to patients.
LifeMD’s Q4 2025 results—$46.9 million in revenue and $19.2 million in net income—demonstrate the company’s strong financial foundation, with a 25% year‑over‑year revenue increase and a 309% rise in Adjusted EBITDA to $15.3 million. The new subscription program is expected to contribute to the company’s 13%–19% revenue growth guidance for 2026 by expanding patient access and improving adherence.
"Our inclusion in the Wegovy subscription program is a natural extension of our established relationship with Novo Nordisk. This program deepens the value of our collaboration and adds meaningful financial savings for the patients we serve," said Justin Schreiber, Chairman and CEO of LifeMD. "By integrating subscription pricing with our comprehensive remote patient care model, we're delivering the future of obesity treatment — branded therapy that is more accessible, affordable, and clinically supported."
The program aligns with LifeMD’s broader strategy of scaling its telehealth platform and leveraging high‑margin GLP‑1 therapies. Management has highlighted record patient sign‑ups in the first quarter of 2026 and the launch of oral Wegovy to address cost and access barriers, underscoring the company’s focus on expanding its patient base while maintaining strong profitability.
Overall, the Wegovy subscription program represents a significant milestone for LifeMD, reinforcing its position as a leading provider of remote weight‑management care and setting the stage for continued growth in the competitive GLP‑1 market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.